Hyperandrogenism and excess weight gain

Journal of Pediatric Endocrinology and Metabolism

Volumn 18, Issue SUPPL. 1, 2005, Pages 1199-1205

  Ibáñez, Lourdes ^a   Ferrer, Angela ^b   Marcos, Maria Victoria ^b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DE TERRASSA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; DROSPIRENONE; FLUTAMIDE; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN; ORAL CONTRACEPTIVE AGENT; PRASTERONE SULFATE;

ARTICLE; CARDIOVASCULAR RISK; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; GESTATIONAL AGE; GLUCOSE UTILIZATION; HIRSUTISM; HUMAN; HYPERANDROGENISM; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; LIVER TOXICITY; LOW BIRTH WEIGHT; LOW DRUG DOSE; METABOLIC SYNDROME X; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PERINATAL PERIOD; PRECOCIOUS PUBERTY; PREVALENCE; PRIMARY PREVENTION; SYMPTOM; WEIGHT GAIN;

EID: 29644441519     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/jpem.2005.18.s1.1199     Document Type: Article

References (59)

1. Asunción M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale H. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438.
2. Baumann EE, Rosenfield RL Polycystic ovary syndrome in adolescence. Endocrinologist 2002; 12: 333-348.
3. Ibañez L, Potau N, Zampolli M, Prat N, Gussinyé M, Saenger P, Vicens-Calvet E, Carrascosa A. Source localization of androgen excess in adolescent girls. J Clin Endocrinol Metab 1994; 79: 1778-1784.
4. Knochenhauer E, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
5. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011.
6. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774-800.
7. Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001; 16: 1255-1260.
8. Boulman N, Levy Y, Leiba R, Shachar S, Linn R, Zinder O, Blumenfeld Z. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab 2004; 89: 2160-2165.
9. Ibáñez L, Ong K, Ferrer A, Amin R, Dunger D, de Zegher F. Low-dose flutamide-metformin therapy reverses insulin resistance and reduces fat mass in non-obese adolescents and young women with ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88: 2600-2606.
10. Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89: 1592-1597.
11. Orio F Jr, Palomba S, Cascella T, Di Biase S, Manguso F, Tauchmanová L, Nardo LG, Labella D, Savastano S, Russo T, Zullo F, Colao A, Lombardi G. The increase of leukocytes as a new putative marker of low grade chronic inflammation and early cardiovascular risk in the polycystic ovary syndrome. J Clin Endocrinol Metab 2005; 90: 2-5.
12. Després JP, Lamarche B, Mauriège P, Cantin B, Dagenais G, Moorjani S, Lupien PJ. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
13. Rexrode KM, Pradhan A, Manson JE, Buring JE, Ridker PM. Relationship total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol 2003; 13: 674-682.
14. Sam S, Dunaif A. Polycystic ovary: syndrome XX? Trends Endocrinol Metab 2003; 14: 365-370.
15. Corbould A, Kim YB, Youngren JF, Pender C, Kahn BB, Lee A, Dunaif A. Insulin resistance in the skeletal muscle of womeh with PCOS involves intrinsic and acquired defects in insulin signaling. Am J Physiol Endocrinol Metab 2005; 288: E1047-1054.
16. Bavdekar A, Yajnik CS, Fall,CH, Bapat S, Pandit AN, Deshpande V, Bhave S, Kellingray SD, Joglekar C. Insulin resistance syndrome in 8-year-old Indian children: small at birth, big at 8 years, or both? Diabetes 1999; 48: 2422-2429.
17. Crowther NJ, Cameron N, Trusler J, Gray IP. Association between poof glucose tolerance and rapid postnatal weight gain in seven-year-old children. Diabetologia 1998; 41: 1163-1167.
18. Garnett SP, Cowell CT, Baur LA, Fay RA, Lee J, Coakley J, Peat J K, Boulton TJ. Abdominal fat and birth size in healthy prepubertal children. Int J Obes Rel Metab Dis 2001; 25: 1667-1673.
19. Ong KKL, Ahmed ML, Emmett PM, Preece MA, Dunger DB. Association between postnatal catch-up growth and obesity in childhood: prospective cohort study. Br Med J 2000; 320: 967-971.
20. Ibáñez L, Ong K, Potau N, Marcos MV, de Zegher F, Dunger D. Insulin gene VNTR genotype and the low birthweight, precocious pubarche and hyperinsulinism sequence. J Clin Endocrinol Metab 2001; 86: 5788-5793.
21. Ibáñez L, Ong K Mongan N, Jäaskeläinen J, Marcos MV, Hughes I, de Zegher F, Dunger D. Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism. J Clin Endocrinol Metab 2003; 88: 3333-3338.
22. Petry CJ, Ong KK, Michelmore KF, Artigas S, Wingate DL, Balen AH, de Zegher F, Ibáñez L, Dunger DB. Association of aromatase (CYP 19) gene variation with features of hyperandrogenism in two populations of young women. Hum Reprod 2005; 20: 1837-1843.
23. Rosenfeld RG. Insulin-like growth factors and the basis of growth. N Engl J Med 2003; 349: 2184-2186.
24. Ozanne SE, Olsen GS, Hawn LL, Tingey KJ, Nave BT, Wang CL, Hartil K, Petry CJ, Buckley AJ, Mosthaf-Seedorf L. Early growth restriction leads to down regulation of protein kinase C zeta and insulin resistance in skeletal muscle. J Endocrinol 2003; 177: 235-241.
25. Ozanne SE, Jensen CB, Tingey KJ, Storgaard H, Madsbad S, Vaag AA. Low birthweight is associated with specific changes in muscle insulin-signalling protein expression. Diabetologia 2005; 48: 547-552.
26. Cettour-Rose P, Samec S, Russell AP, Summermatter S, Mainieri D, Carrillo-Theander C, Montani JP, Seydoux J, Rohner-Jeanrenaud F, Dulloo AG. Redistribution of glucose from skeletal muscle to adipose tissue during catch-up fat. A link between catcb-up growth and later metabolic syndrome. Diabetes 2005; 54: 751-756.
27. Lapillonne A, Braillon P, Claris O, Chatelain P, Delmas PD, Salle BL. Body composition in appropriate and in small for gestational age infants. Acta Paediatr 1997; 86: 196-200.
28. Soto N, Bazaes RA, Peña V, Salazar T, Ávila A, Iñíguez G, Ong KK, Dunger DB, Mericq MV. Insulin sensitivity and secretion are related to catch-up growth in small-for-gestational-age infants at age 1 year: results from a prospective study cohort. J Clin Endocrinol Metab 2003; 88: 3645-3650.
29. Ong K, Potau N, Petry CJ, Ness AF, Jones I, the ALSPAC Study Team, Honour JW, de Zegher F, Ibáñez L, Dunger DB. Adrenarche is paradoxically modulated by prenatal and postnatal weight gain. J Clin Endocrinol Metab 2004; 89: 2647-2651.
30. Forsen T, Eriksson JG, Tuomilehto J, Osmond C, Barker DJ. Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study. Br Med J 1999; 319: 1403-1407.
31. Ibáñez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, de Zegher F. Anovulation in eumenorrheic, non-obese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 5702-5705.
32. Ibáñez L, Valls C, Miró E, Marcos MV, de Zegher F. Early menarche and subclinical ovarian hyperandrogenism in girls with reduced adult height after low birthweight. J Pediatr Endocrinol Metab 2002; 15: 431-433.
33. Ibáñez L, Potau N, Marcos MV, de Zegher F. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age. J Clin Endocrinol Metab 1999; 84: 4739-4741.
34. Ibáñez L, DiMartino-Nardi J, Potau N, Saenger P. Premature adrenarche - normal variant or forerunner of adult disease? Endocr Rev 2000; 21: 671-696.
35. Ibáñez L, de Zegher F, Francois I, Potau N. Precocious pubarche, hyperinsulinism and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab 1998; 83: 3558-3662.
36. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low birthweight effect. Clin Endocrinol 2001; 55: 667-672.
37. Neville KA, Walker JL. Precocious pubarche is associated with SGA, prematurity, weight gain, and obesity. Arch Dis Child 2005; 90: 258-261.
38. Ibáñez L, Potau N, Zampolli M, Riqué S, Saenger P, Carrascosa A. Hyperinsulinemia and decreased insulin-like growth factor binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche. J Clin Endocrinol Metab 1997; 82: 2283-2288.
39. Ibáñez L, Potau N, Chacón P, Pascual P, Carrascosa A. Hyperinsulinemia, dyslipemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 1998; 41: 1057-1063.
40. Ibáñez L, Ong K, de Zegher F, Marcos MV, del Rio L, Dunger D. Fat distribution in non-obese girls with and without precocious pubarche: central adiposity related to insulinemia and androgenemia from pre-puberty to post-menarche. Clin Endocrinol 2003; 58: 372-379.
41. Ibáñez L, Potau N, de Zegher F. Precocious pubarche, dyslipidemia and low IGFBP-1 in girls: relation to reduced prenatal growth. Pediatr Res 1999; 46: 320-322.
42. Cook S. The metabolic syndrome: antecedent of adult cardiovascular disease in pediatrics. J Pediatr 2004; 145: 427-430.
43. Ibáñez L, de Zegher F, Potau N. Anovulation after precocious pubarche: early markers and time course in adolescence. J Clin Endocrinol Metab 1999; 84: 2691-2695.
44. Ibáñez L, Ferrer A, Ong K, Amin R, Dunger D, de Zegher F. Insulin sensitization early post-menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004; 144: 23-29.
45. Ibáñez L, Valls C, Marcos MV, Ong K, Dunger D, de Zegher F. Insulin sensitization for girls with precocious pubarche and with risk for polycystic ovary syndrome: effects of prepubertal initiation and postpubertal discontinuation of metformin. J Clin Endocrinol Metab 2004; 89: 4331-4337.
46. Ibáñez L, de Zegher F. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and anti-atherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at start and after more than one year of therapy. J Clin Endocrinol Metab 2005; 90: 39-43.
47. Ibáñez L, Valls C, Potau N, Marcos MV, de Zegher F. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000; 85: 3526-3530.
48. Ibáñez L, de Zegher F. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity. J Clin Endocrinol Metab 2004; 89: 1592-1597.
49. Ibáñez L, Fucci A, Valls C, Ong K, Dunger D, de Zegher F. High neutrophil count in small-for-gestational-age children: contrasting effects of metformin and growth hormone therapy. J Clin Endocrinol Metab 2005; 90: 3435-3439.
50. Ibáñez L, Jaramillo A, Ferrer A, de Zegher F. High neutrophil count in girls and women with hyperinsulinemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception. Hum Reprod 2005; 20: 2457-2462.
51. Ibáñez L, Jaramillo A, Ferrer A, de Zegher F. Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women. Hum Reprod 2005; in press.
52. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002; 16: 163-272.
53. Ten S, Maclaren N. Insulin resistance syndrome in children. J Clin Endocrinol Metab 2004; 89: 2526-2539.
54. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA. Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 2003; 18: 2289-2293.
55. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med 2005; 352: 1223-1236.
56. Gambineri A, Pelusi C, Manicardi E, Vicennati V, Cacciari M, Moreslli-Labate AM, Pagotto U, Pasquali R. Glucose intolerance in a large cohort of Mediterranean women with polycystic ovary syndrome. Diabetes 2004; 53: 2353-2358.
57. Arslanian SA, Lewy V, Danadian K, Saad R. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002; 87: 1555-1559.
58. Hoeger KM, Kochman L, Wixom N, Craig K, Miller RK, Guzick DS. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82: 421-429.
59. Strauss R, Knight J. Influence of the home environment on the development of obesity in children. Pediatrics 1999; 103: e85.